Vericel Corporation
VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple fullā¦ read more
Healthcare
Biotechnology
27 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$36.28
Price+1.43%
$0.51
1Y
Price
Market Cap
$1.831b
Small
Price/Earnings 3y Avg5y Avg
259.1x
Premium
Premium
Financials Overview
Key metrics over the past few years-11.4%
EBITDA Margin-8.9%
Net Profit Margin-12.9%
Free Cash Flow MarginRevenue
$249.119m
+8.6%
1y CAGR+11.3%
3y CAGR+15.0%
5y CAGREarnings
$7.107m
+124.8%
1y CAGR+27.4%
3y CAGR-69.7%
5y CAGREPS
$0.12
+114.3%
1y CAGR+25.2%
3y CAGR-72.8%
5y CAGRBook Value
$306.809m
$435.608m
Assets$128.799m
Liabilities$101.538m
DebtDebt to Assets
23.3%
85.3x
Debt to EBITDAFree Cash Flow
$64.231m
-73.9%
1y CAGR-49.6%
3y CAGR-26.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company